LENZ Therapeutics (NASDAQ:LENZ) Given "Buy" Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of LENZ Therapeutics (NASDAQ:LENZ - Free Report) in a research note released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $38.00 price target on the stock.

Several other research analysts have also issued reports on LENZ. TD Cowen initiated coverage on shares of LENZ Therapeutics in a research report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 price target for the company. Piper Sandler assumed coverage on LENZ Therapeutics in a report on Monday, April 14th. They issued an "overweight" rating and a $51.00 target price for the company. Finally, Citigroup boosted their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday, March 20th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $46.60.

LENZ Therapeutics Trading Up 1.6 %

LENZ stock traded up $0.39 during trading on Wednesday, reaching $24.21. 55,584 shares of the stock were exchanged, compared to its average volume of 181,337. The stock has a 50 day simple moving average of $23.47 and a 200-day simple moving average of $27.14. The company has a market capitalization of $666.82 million, a P/E ratio of -5.08 and a beta of 0.43. LENZ Therapeutics has a twelve month low of $14.42 and a twelve month high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Equities analysts predict that LENZ Therapeutics will post -2.18 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in LENZ Therapeutics in the fourth quarter worth $29,000. KLP Kapitalforvaltning AS acquired a new position in LENZ Therapeutics during the 4th quarter worth about $46,000. Tower Research Capital LLC TRC grew its holdings in LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after acquiring an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC acquired a new stake in LENZ Therapeutics in the 4th quarter valued at about $67,000. Finally, GAMMA Investing LLC raised its stake in shares of LENZ Therapeutics by 5,254.1% in the first quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock worth $150,000 after acquiring an additional 5,727 shares during the last quarter. 54.32% of the stock is owned by institutional investors and hedge funds.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.